What’s the current market cap for CryoPort stock?

CryoPort (CYRX) has a market cap of $757m as of June 22, 2026.

What is the P/E ratio for CryoPort stock?

The price to earnings (P/E) ratio for CryoPort (CYRX) stock is 10.47 as of June 22, 2026.

Does CryoPort stock pay dividends?

No, CryoPort (CYRX) stock does not pay dividends to its shareholders as of June 22, 2026.

When is the next CryoPort dividend payment date?

CryoPort (CYRX) stock does not pay dividends to its shareholders.

What is the beta indicator for CryoPort?

CryoPort (CYRX) has a beta rating of 1.75. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy CryoPort stock | $CYRX Share Price

13:30

15:10

16:45

18:25

20:00

About CryoPort

CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.

Ticker

$CYRX

Sector

Health

Primary listing

NASDAQ

Employees

688

Headquarters

Brentwood, United States

Website

www.cryoportinc.com

CryoPort Metrics

BasicAdvanced

$757m

10.47

$1.43

1.75

What the Analysts think about CryoPort

Analyst ratings (Buy, Hold, Sell) for CryoPort stock.

Bulls say / Bears say

Cryoport’s revenue increased 16% year-over-year to $47.8 million in Q1 2026, showing ongoing momentum in both Life Sciences Services and Products.

Total gross margin widened by 40 basis points to 45.8% in Q1 2026, demonstrating operational leverage as the company scales.

Management raised full-year fiscal 2026 revenue guidance to $192 million–$196 million, reflecting confidence in continued market growth.

Cryoport reported a net loss of $10.5 million in Q1 2026, showing the company is still unprofitable despite revenue growth.

Adjusted EBITDA from continuing operations was negative $0.6 million in Q1 2026. Management does not expect to reach break-even until the second half of the fiscal year.

Plans to expand facilities in Paris (Q3 2026) and Santa Ana, California (Q4 2026) could raise capital expenditures and delay profitability if market growth slows.

Data summarised monthly by Lightyear AI. Last updated on 31 May 2026.

CryoPort Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

CryoPort Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

Cryoport’s revenue increased 16% year-over-year to $47.8 million in Q1 2026, showing ongoing momentum in both Life Sciences Services and Products.

Total gross margin widened by 40 basis points to 45.8% in Q1 2026, demonstrating operational leverage as the company scales.

Management raised full-year fiscal 2026 revenue guidance to $192 million–$196 million, reflecting confidence in continued market growth.

Cryoport reported a net loss of $10.5 million in Q1 2026, showing the company is still unprofitable despite revenue growth.

Adjusted EBITDA from continuing operations was negative $0.6 million in Q1 2026. Management does not expect to reach break-even until the second half of the fiscal year.

Plans to expand facilities in Paris (Q3 2026) and Santa Ana, California (Q4 2026) could raise capital expenditures and delay profitability if market growth slows.

Data summarised monthly by Lightyear AI. Last updated on 31 May 2026.

About CryoPort

Ticker

Employees

CryoPort Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about CryoPort

Analyst Ratings

Bulls say / Bears say

CryoPort Financial Performance

Income Statement

CryoPort Earnings Performance

Earnings per share (EPS)

Buy $CYRX

Lightyear

Legal

Work with us

Bulls say / Bears say

CryoPort/$CYRX

About CryoPort

Ticker

Employees

CryoPort Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about CryoPort

Analyst Ratings

Bulls say / Bears say

CryoPort Financial Performance

Income Statement

CryoPort Earnings Performance

Earnings per share (EPS)

What’s the current market cap for CryoPort stock?

What is the P/E ratio for CryoPort stock?

Does CryoPort stock pay dividends?

When is the next CryoPort dividend payment date?

What is the beta indicator for CryoPort?

Bulls say / Bears say